Kirkland & Ellis represented Linden Capital Partners, Wilmer Cutler Pickering Hale and Dorr represented Alcresta Therapeutics and Wilson Sonsini Goodrich & Rosati advised HealthQuest Capital. Linden...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Carisma Therapeutics Inc. on the deal. Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, announced a strategic collaboration...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised PerkinElmer on the deal while Pillsbury Winthrop Shaw Pittman represented BioLegend. PerkinElmer, a global leader committed to innovating for...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Apellis Pharmaceuticals on the deal. Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. (Nasdaq: BEAM), announced that they...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale, Dorr LLP and Skrine and Bär & Karrer advised The Tecan Group on the deal, while Schiff Hardin LLP represented Paramit Corporation....
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr LLP advised Sanofi on the deal. Sanofi, a global biopharmaceutical company focused on human health, announced its acquisition of Tidal...
You must be a Standard 1 Year member to access this content.
